UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): January 7, 2020

 

 

 

MARRONE BIO INNOVATIONS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-36030   20-5137161

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

1540 Drew Avenue, Davis, CA 95618

(Address of Principal Executive Offices, and Zip Code)

 

(530) 750-2800

Registrant’s Telephone Number, Including Area Code

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  [  ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  [  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  [  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  [  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.00001 par value   MBII   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 
 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Secured Revolving Borrowing

 

On January 7, 2020, Marrone Bio Innovations, Inc. (the “Company”) entered into a Second Amendment to the Company’s Invoice Purchase Agreement (the “Amendment”) dated as of March 24, 2017 with LSQ Funding Group, L.C. (“LSQ”).

 

The amendment, among other things, (i) increases the amount in which LSQ may elect to purchase up to $20,000,000 of eligible customer invoices from the Company from $7,000,000; (ii) increases the advance rate to 90% from 85% and 70% from 60%, respectively, of the face value of domestic and international receivables being sold; (iii) decreases the invoice purchase fee rate from 0.40% to 0.25%; (iv) increases the funds usage fee from 0.020% to 0.025%; (v) extends the 0% aging and collection fee percentage charged at the time when the purchased invoice is collected from 90 days to 120 days, and increases the fee percentage charged thereafter from 0.35% to 0.75%; and (vi) decreases the early termination fee from 0.75% to 0.50%.

 

In addition to the Amendment, the Company simultaneously entered into an Amended Inventory Financing Addendum (the “Addendum”) with LSQ. The Addendum allows the Company to request an advance up to the lesser of (i) 100% of the Company’s unpaid finished goods inventory; (ii) 65% of the appraised value of the Company’s inventory performed on or on behalf of LSQ; or (iii) $3,000,000. Funds advance under the Addendum are subject to a monthly inventory management fee of 0.5% on the average monthly inventory funds available and a daily interest rate of 0.025%.

 

The Amendment and the Addendum are filed herewith as Exhibits 10.1 and 10.2, respectively, and are incorporated herein by reference, and the foregoing descriptions are qualified in their entirety by the terms contained therein.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

 

Item 8.01. Other Events.

 

On January 9, 2019, the Company issued a press release announcing its amendment to the secured revolving borrowing agreements. A copy of the press release as attached hereto as Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit

Number

  Description
 
10.1   Amendment No. 2 dated as of January 7, 2020, to Invoice Purchase Agreement dated March 24, 2017
     
10.2  

Amended Inventory Financing Addendum, dated as of January 6, 2020, to Invoice Purchase Agreement dated March 24, 2017

     
99.1   Press release dated January 9, 2020

 

 
 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MARRONE BIO INNOVATIONS, INC.
   
Date: January 9, 2020 By: /s/ Linda V. Moore
  Name: Linda V. Moore
  Title: Executive Vice President, General Counsel, Secretary and Chief Compliance Officer

 

 
 

 

 

Exhibit 10.1

 

SECOND AMENDMENT TO INVOICE PURCHASE AGREEMENT

 

This Second Amendment (“Second Amendment”) to the Invoice Purchase Agreement entered into on March 24, 2017 (“Invoice Purchase Agreement”) is made and entered into on January 6, 2020, by and between Marrone Bio Innovations, Inc., a Delaware corporation (the “Seller”) with offices located at 1540 Drew Ave, Davis, CA 95618 and LSQ Funding Group LC. (“Purchaser”), a Florida Limited Liability company, with offices located at 315 E Robinson Street Suite 201, Orlando, FL 32801 (each a “Party,” collectively the “Parties”).

 

RECITALS

 

  A. Marrone Bio Innovations, Inc. and LSQ are parties to that certain Invoice Purchasing Agreement dated as of March 24, 2017 (as at any time amended, modified, restated, or supplemented, the “Agreement”).
  B. The Parties intend to substitute the below advance rates, fees, and termination

 

NOW, THEREFORE, it is agreed as follows that the following amended sections shall replace following sections of the Agreement

 

  1. Section 1.1 of the Agreement, the “Advance Rate,” is hereby amended, in part, to increase the rate from 85% to 90%, effective immediately. The rate for international Accounts is to increase from 60% to 70%, effective immediately. All other terms of Section 1.1, with the exception of this amendment, remain as originally written.
     
  2. Section 1.2 of the Agreement, the “Aging and Collection Fee,” is hereby amended, in part, to adjust the rate from 0% from day 1 through day 120; and from 0.75% from day 121 thereafter, effective immediately. All other terms of Section 1.2 with the exception of this amendment, remain as originally written.
     
  3. Section 1.13 of the Agreement, the Funds Usage Fee,” is hereby amended, in part, to increase the rate from 0.020% to 0.025%, effective immediately. All other terms of Section 1.13 with the exception of this amendment, remain as originally written.
     
  4. Section 1.15 of the Agreement, the “Invoice Purchase Fee,” is hereby amended, in part, to reduce for a rate from 0.40% to 0.25%, effective immediately. Invoices with terms over 120 days, will incur a 1% premium fee on the gross amount of the invoice. All other terms of Section 1.15, with the exception of this amendment, remain as originally written.
     
  5. Section 1.17 of the Agreement, the “Maximum Amount,” is hereby amended, in part, to increase from $7,000,000.00 to $20,000,000.00, effective immediately. All other terms of Section 1.17, with the exception of this amendment, remain as originally written.

 

Page 1 of 3
 

 

  6. Section 21 of the Agreement, the “Term and Termination Date,” is hereby amended, in part, to provide that Seller provides written notice of its intention to terminate at least 30 days and not greater than 90 days prior to each anniversary date and that the next date for termination of the Agreement is July 31, 2020. Thereafter, the Agreement will renew automatically on an annual basis unless terminated pursuant to its terms.
     
  7. Section 21.1 of the Agreement, is hereby amended in part, if effective notice by Seller under Section 21 above is not provided, then in addition to any other fees due under this Agreement, Seller agrees that it will pay an early termination fee equal to .50% multiplied by the Maximum Amount set forth in Section 1.17 herein multiplied by the number of months remaining in the Term or any Renewal Term (the “Early Termination Fee”).
     
  8. Section 21.2 of the Agreement, is hereby amended in part, if Seller intends to refinance with a bank its obligations under this Agreement, Seller may terminate this Agreement prior to the end of the Term or any Renewal Term by providing Purchaser 60 days’ prior written notice and refinancing with bank or institution. If such notice is provided and Seller refinances with the bank or institution, no Early Termination Fee pursuant to Section 21.1 shall be due.
     
  9. Section 21.3 removed

 

Except as modified herein, all terms and conditions of the Agreement, taken together with this Second Amendment, shall remain in full force and effect. The parties agree that: (i) this Second Amendment may be executed and delivered by the parties in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which counterparts, taken together, shall constitute [but] one and the same instrument; (ii) capitalized terms used herein but not otherwise defined herein shall have the meanings ascribed to them in the Agreement; (iii) this Second Amendment modifies and amends only those specific terms of the Agreement expressly referenced herein; and (iv) all other terms of the Agreement are hereby restated and shall remain in full force and effect, and shall constitute the legal valid, binding and enforceable obligations of the parties.

 

IN WITNESS WHEREOF, the parties have executed this Second Amendment to the Agreement as of the day and year first above written.

 

[Signature page to follow]

 

Page 2 of 3
 

 

AGREED AND ACCEPTED BY

 

LSQ Funding Group, L.C.

 

By: /s/ William M Samuelson  
Name: William M Samuelson  
Title: EVP  
Date: January 7, 2020  

 

AGREED AND ACCEPTED BY:

 

Marrone Bio Innovations, Inc.

 

By: /s/ Pamela G. Marrone  
Name: Pamela G. Marrone  
Title: CEO & Founder  
Date: January 6, 2020  

 

Page 3 of 3
 

 

Exhibit 10.2

 

AMENDED INVENTORY FINANCING ADDENDUM

 

This Amended Inventory Financing Addendum to the Invoice Purchase Agreement (“Addendum”) is dated as of January 6, 2020 by and between Marrone Bio Innovations, Inc., a Delaware Corporation (“Seller”) and LSQ Funding Group, L.C. (“Purchaser”).

 

RECITALS

 

A. Seller and Purchaser are parties to the Invoice Purchase Agreement pursuant to which Purchaser buys Accounts from Seller.

 

B. Seller has requested that Purchaser make advances to Seller to enable Seller to acquire and carry inventory.

 

C. Purchaser is willing to make said advances to Seller so long as such advances do not exceed an agreed to percentage of Seller’s eligible inventory, as more set forth herein.

 

D. This Addendum is an Addendum to the Invoice Purchase Agreement and shall be governed by and made a part thereof.

 

NOW, THEREFORE, in consideration of the premises, and intending to be legally bound hereby, the Parties hereby agree as follows:

 

ADDENDUM

 

1. CERTAIN DEFINITIONS AND INDEX TO DEFINITIONS.

 

1.1 Unless otherwise defined herein, any capitalized terms used herein shall have the meanings ascribed in the Invoice Purchase Agreement. All terms used herein that are defined in the Uniform Commercial Code shall have the meanings ascribed thereto therein. As used herein, the following terms shall have the following meanings:

 

1.1.1 “Advance” - Any funding by Purchaser to Seller hereunder or under the Invoice Purchase Agreement, or payments made by Purchaser on account of any guarantees issued by Purchaser on behalf of Seller.

 

1.1.2 “Allowable Amount” - The lesser of:

 

(a) 100% of the unpaid face amount of Eligible Accounts;

 

(b) 65% of Net Orderly Liquidation Value; or

 

(c) The Maximum Amount.

 

1.1.3 “Borrowing Base Certificate” - A request for an Advance, in a form acceptable to Purchaser, calculating Seller’s funding availability hereunder.

 

1.1.4 “Collateral” - Any collateral now or hereafter securing the obligations of Seller to Purchaser.

 

Page 1 of 7
 

 

1.1.5 5 “Default Rate” - 18% above the Interest Rate.

 

1.1.6 “Eligible Inventory” - Finished goods Inventory of Seller which is:

 

(a) Subject to Purchaser’s first priority, perfected security interest;

 

(b) Not owned by Seller for more than 365 days; and

 

(c) Otherwise acceptable to Purchaser in its reasonable sole discretion.

 

1.1.7 “Event of Default” - Default in the performance of any obligation now or hereafter owing by Seller to Purchaser, including but not limited to obligations arising hereunder or under the Invoice Purchase Addendum.

 

1.1.8 “Inventory Management Fee” - .5% charged monthly on the average monthly inventory funds availability.

 

1.1.9 “Invoice Purchase Agreement” - That certain Invoice Purchase Agreement between Seller and Purchaser dated as of March 24, 2017.

 

1.1.10 “Interest Rate” - .025% per day.

 

1.1.11 “Funding Balance” - The unpaid balance of Advances and any other charges owing by Seller to Purchaser hereunder.

 

1.1,12 “Maximum Amount” - $3,000,000.00.

 

1.1.13 “Net Orderly Liquidation Value” -Means the Net Orderly Liquidation Value as determined by the inventory appraisal of JC&M dated September 9, 2019 (Effective date June 30, 2019), and from further inventory appraisals performed by or on behalf of Secured Party from time to time.

 

1.1.14 “Purchased Account” - See Section 1.23 of the Invoice Purchase Agreement.

 

2. ADVANCES TO SELLER.

 

2.1 Advances.

 

2.1.1 Subject to the terms and conditions of this Addendum, from the date on which this Addendum becomes effective until the Termination Date, Purchaser, may, in its sole discretion, from time to time, at the request of Seller, make Advances to Seller so long as, before and after such Advance the Funding Balance does not exceed the Allowable Amount.

 

2.1.2 Upon the request of Seller for an Advance pursuant to this Addendum, the Purchaser may, in Purchaser’s sole discretion, make Advances to Seller pursuant to this Addendum or the Invoice Purchase Agreement.

 

Page 2 of 7
 

 

2.2 Repayment.

 

2.2.1 Seller shall immediately repay any portion of the Funding Balance that exceeds the Allowable Amount.

 

2.2.2 The Funding Balance shall be due and payable without notice or demand on the date of termination of the Invoice Purchase Agreement.

 

2.3 Borrowing Base Certificate. Each request from Seller for an Advance shall be accompanied by a Borrowing Base Certificate, completed and signed by Seller.

 

2.4 Factoring Account. All Advances may be made, in Purchaser’s sole discretion, by a credit by Purchaser to Seller’s account under the Invoice Purchase Agreement and all sums due hereunder may be debited to said account when due.

 

2.5 Limitation on Borrowing under this Rider. At any time, in Purchaser’s sole discretion, Purchaser may make an advance and apply such advance in reduction of the Face Amount of any Purchased Account under the Invoice Purchase Agreement.

 

3. FEES.

 

3.1 Basic Interest. Interest on the Funding Balance shall be payable monthly, in arrears, shall be computed at the Interest Rate, and shall be due on the first day of each month following the accrual thereof

 

3.2 Debit to Funding Balance. Purchaser may debit the Funding Balance on the first day of each month for interest accrued hereunder during the preceding month.

 

3.3 Default Interest.

 

3.3.1 Immediately upon the occurrence of an Event of Default, interest shall accrue and be payable at the Default Rate.

 

3.3.2 Purchaser’s failure to assess interest at the Default Rate as provided hereunder shall not be deemed a waiver by Purchaser to charge such Default Rate.

 

3.4 Calculation of Interest. All interest charged hereunder shall be computed on the basis of a three hundred sixty (360) day year for the actual number of days elapsed.

 

3.5 Inventory Management Fee. The fee as set forth in Section 1.1.8.

 

4. COVENANTS, REPRESENTATIONS AND WARRANTIES BY SELLER.

 

4.1 Inventory Listing. Seller shall furnish to Purchaser, in form and substance satisfactory to Purchaser, a listing of all Seller’s Inventory, based ‘upon a physical count taken by Seller every six months and whenever requested by Purchaser.

 

4.2 Inspections. During usual business hours, permit Purchaser, without notice to Seller, to periodically:

 

Page 3 of 7
 

 

4.2.1 Have access to all premises where Seller’s Inventory is located for the purposes of inspecting (and removing, if after the occurrence of an Event of Default) any of the Eligible Inventory, and

 

4.2.2 To inspect, audit, make copies of, and make extracts from Seller’s records as Purchaser may request.

 

4.3 Use of Seller’s Employees and Assets. Use any of Seller’s personnel, equipment, including computer equipment, programs, printed output and computer readable media, supplies and premises for the enforcement of any of Purchaser’s rights regarding Seller’s Inventory.

 

4.4 Maintenance of Insurance.

 

4.4.1 Seller will maintain with financially sound and reputable insurers insurance with respect to its properties and business against such casualties and contingencies as shall be in accordance with general practices of businesses engaged in similar activities in similar geographic areas. Such insurance shall be in such minimum amounts that the Seller will not be deemed a co-insurer under applicable insurance laws, regulations, and policies and otherwise shall be in such amounts, contain such terms, be in such forms and be for such periods as may be reasonably satisfactory to the Purchaser. In addition, all such insurance shall be payable to the Purchaser under a Purchaser Loss Payable Endorsement. Without limiting the foregoing, the Seller will:

 

(a) Keep all of its physical property insured with casualty or physical hazard insurance on an “all risks” basis, with broad form flood and electronic data processing coverage, with a full replacement cost endorsement and an “agreed amount” clause in an amount equal to 100% of the full replacement cost of such property;

 

(b) Maintain, in amounts and with deductibles equal to those generally maintained by businesses engaged in similar activities in similar geographic areas, general public liability insurance against claims of bodily injury, death, or property damage occurring, on, in or about the properties of the Seller; business interruption insurance; and product liability insurance.

 

4.4.2 In the event that Seller fails to maintain such insurance, Purchaser may obtain such insurance at Seller’s expense, and, after an Event of Default, to adjust or settle any claim or other matter under or arising pursuant to such insurance or to amend or cancel such insurance.

 

5. EVENT OF DEFAULT.

 

5.1 Upon the occurrence of an Event of Default under this Addendum or the Invoice Purchase Agreement, all sums due hereunder shall be immediately due and payable without notice or demand.

 

Page 4 of 7
 

 

6. STANDARDS FOR EXERCISING REMEDIES.

 

6.1 To the extent that applicable law imposes duties on the Purchaser to exercise remedies in a commercially reasonable manner, the Seller acknowledges and agrees that it is not commercially unreasonable for the Purchaser:

 

6.1.1 To not incur expenses to prepare Seller’s Inventory for disposition or otherwise to complete raw material or work in process into finished goods or other finished products for disposition;

 

6.1.2 To fail to obtain third party consents for access to the Eligible Inventory to be disposed of, or to obtain or, if not required by other law, to fail to obtain governmental or third party consents for the collection or disposition of the Eligible Inventory to be collected or disposed of;

 

6.1.3 To advertise dispositions of Collateral through publications or media of general circulation, whether or not the Collateral is of a specialized nature;

 

6.1.4 To hire one or more professional auctioneers to assist in the disposition of Collateral, whether or not the collateral is of a specialized nature;

 

6.1.5 To dispose of Collateral by using Internet sites that provide for the auction of assets of the types included in the Collateral or that have the reasonable capability of doing so, or that match buyers and sellers of assets;

 

6.1.6 To dispose of assets in wholesale rather than retail markets;

 

6.1.7 To disclaim all disposition warranties; or

 

6.1.8 To purchase insurance or credit enhancements to insure the Purchaser against risks of loss, collection or disposition of Collateral or to provide to the Purchaser a guaranteed return from the collection or disposition of Collateral.

 

6.2 Seller acknowledges that the purpose of this Section 6 is to provide non exhaustive indications of what actions or omissions by the Purchaser would not be commercially unreasonable in the Purchaser’s exercise of remedies against the Collateral and that other actions or omissions by the Purchaser shall not be deemed commercially unreasonable solely on account of not being indicated in this Section. Without limitation upon the foregoing, nothing contained herein shall be construed to grant any rights to the Seller or to impose any duties on the Purchaser that would not have been granted or imposed by this Addendum or by applicable law in the absence of this Section 6

 

7. PROCEEDS AND EXPENSES OF DISPOSITIONS.

 

7.1 Seller shall pay to the Purchaser on demand any and all expenses, including reasonable attorneys’ fees and disbursements, incurred or paid by the Purchaser in protecting, preserving, or enforcing the Purchaser’s rights under or in respect of any of the Obligations or any of the Collateral. After deducting all of said expenses, the residue of any proceeds of collection or sale of the Obligations or Collateral shall, to the extent actually received in cash, be applied to the payment of the Obligations in such order or preference as the Purchaser may determine, notwithstanding contrary instructions received by Purchaser from the Seller or any other third party.

 

Page 5 of 7
 

 

8. LIQUIDATION SUCCESS PREMIUM.

 

8.1 If Seller shall substantially cease operating as a going concern, and the proceeds of Collateral created after the occurrence of an Event of Default (the “Default”) are in excess of the Obligations at the time of Default, Seller shall pay to Purchaser a liquidation success premium of ten percent of the amount of such excess.

 

9. GENERAL PROVISIONS.

 

9.1 Survival. The representations and warranties and Seller’s covenants hereunder shall survive the (a) closing of the Addendum; and (b) termination of this Addendum, and Purchaser may enforce such representations and warranties and covenants at any time.

 

9.2 Incorporation by Reference to Provisions of the Invoice Purchase Agreement. Any provision contained within the Invoice Purchase Agreement not otherwise inconsistent with the provisions covered herein shall be incorporated by reference and applicable to this Addendum as if fully set forth herein. Any provision in the Invoice Purchase Agreement that may be inconsistent with a provision of this Addendum shall first be interpreted in a common-sense manner that makes it consistent with the applicable to this Addendum to the extent possible and if thereafter it is still inconsistent, such inconsistent provision from the Invoice Purchase Agreement shall not apply to this Addendum.

 

9.2.1 Without limiting the foregoing, this Addendum and the rights and obligations of Purchaser and Seller under this Addendum shall be governed by and construed and interpreted in accordance with Section 14 (Account Stated); Section 20 (Amendment and Waiver); Section 22 (No Lien Termination without Release); Section 23 (Conflict); Section 24 (Severability); Section 25 (Expenses); Section 26 (Entire Agreement); Section 27 (Choice of Law); Section 28 (Jury Waiver); Section 29 (Venue; Jurisdiction); Section 30 (Counterparts); Section 31 (Notice); and Section 32 (Successors and Assigns).

 

Page 6 of 7
 

 

IN WITNESS WHEREOF, the parties hereto have caused this Addendum to be duly executed and delivered by their respective officers thereunto duly authorized as of the date first above written.

 

SELLER: Marrone Bio Innovations, Inc.
     
  By: /s/ Pamela G. Marrone
  Name: Pamela G. Marrone
  Title: CEO and Founder

 

PURCHASER: LSQ Funding Group, L.C.
     
  By: /s/ William Samuelson
    William Samuelson
    Director of Operations

 

Page 7 of 7
 

 

Exhibit 99.1

 

Marrone Bio Innovations Announces New $23 Million Accounts-Receivable and Inventory-Backed Credit Facilities

 

New Credit Facilities to Address Working Capital Required to Support Growing Sales

 

DAVIS, Calif., Jan. 9, 2020 — Marrone Bio (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today announced a $13.0 million expansion of its existing accounts-receivable credit facility which now totals $20.0 million, as well as the addition of a $3.0 million inventory-backed credit facility to support the Company as it continues to expand its customer base.

 

Pursuant to the terms of the agreement with LSQ Funding Group (“LSQ”), LSQ may elect to purchase up to $20.0 million of eligible customer invoices form the Company, a significant increase from the $7.0 million limit established in 2017. In addition, the Company established a new $3.0 million inventory-backed credit facility with LSQ.

 

“Our partnership with LSQ has given us excellent cost-effective financial vehicles by which we can improve our liquidity and working capital to accommodate our rapid growth,” said Jim Boyd, President and Chief Financial Officer of Marrone Bio Innovations. “I expect these facilities to help address the seasonal demand and varying sales cycles across the various crops and customers we serve. We look forward to continued success in 2020, driving long-term value creation for our shareholders.”

 

“We are pleased to renew our strong working relationship with Marrone Bio Innovations, which has been an excellent client in our portfolio,” said Dan Ambrico, President and CEO at LSQ Funding Group. “The company has utilized our products to enhance its ongoing business success, and the substantial dollar increase reflected in this year’s amendment, as well as the addition of a new inventory-backed credit facility, represents our continued confidence in the growth of their business. We look forward to our continued partnership with Marrone Bio Innovations in the future.”

 

About LSQ

 

LSQ helps businesses better manage their cash flow to make the most of whatever they’ve earned. Offering invoice financing and supply chain finance solutions LSQ provides clients with a simple, secure, and honest funding experience. LSQ blends human insights with the analytical power of technology to develop products that give customers the means to accelerate the flow of business. LSQ, headquartered in Orlando, Florida, has helped 1000s of companies access $24 billion in its 20+ years in business. Learn more about our solutions at https://www.lsq.com/

 

About Marrone Bio Innovations

 

Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to more a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude®, Zelto® Jet Oxide® and Jet Ag® and Zequanox®, with a breakthrough bioherbicide and biofumigant in the Company’s product pipeline. Pro Farm, MBI’s Finland-based subsidiary, employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. Products include UBP-110®, LumiBio™, LumiBio Valta™, LumiBio Kelta™, Foramin®.

 

Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.

 

Marrone Bio Innovations Forward-Looking Statements

 

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements and should not be relied upon as representing MBI’s views as of any subsequent date. Forward-looking statements may include, without limitation, statements regarding the use of and anticipated results from the credit facilities and the assumptions underlying or relating to the foregoing. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, the potential of new revenue generating activities, seasonal, weather, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers.

 

Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.

 

Marrone Bio Innovations Contact:

 
Jim Boyd, President & Chief Financial Officer

Telephone: +1 (530) 750-2800

Email: info@marronebio.com

 

Investor Relations Contact:

 
Greg Falesnik, Managing Director

MZ Group – MZ North America

Main: 949-385-6449

MBII@mzgroup.us

www.mzgroup.us